AZD2693
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Nonalcoholic Steatohepatitis
Conditions
Nonalcoholic Steatohepatitis
Trial Timeline
Mar 15, 2023 → Sep 29, 2025
NCT ID
NCT05809934About AZD2693
AZD2693 is a phase 2 stage product being developed by AstraZeneca for Nonalcoholic Steatohepatitis. The current trial status is completed. This product is registered under clinical trial identifier NCT05809934. Target conditions include Nonalcoholic Steatohepatitis.
What happened to similar drugs?
0 of 6 similar drugs in Nonalcoholic Steatohepatitis were approved
Approved (0) Terminated (3) Active (3)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05919069 | Phase 1 | Completed |
| NCT05809934 | Phase 2 | Completed |
| NCT04483947 | Phase 1 | Completed |
Competing Products
20 competing products in Nonalcoholic Steatohepatitis